Theralase Technologies Inc. V.TLT

New PDT paper mentioning TLD1433

[ScienceFirst]

"1433" mentioned twice.

They need to go deeper on the latest TLD1433 results.  Their article would have been even more upbeat in their conclusion as they could have clearly mentioned a long-awaited breakthrough.  I wrote to these researchers by providing them with the latest mid-Ph. 2 results.

 

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

Mafalda Penetra

, 

Lus G. Arnaut

 & 

Lgia C. Gomes-da-Silva

Article: 2226535 | Received 23 May 2023, Accepted 13 Jun 2023, Published online: 18 Jun 2023

https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2226535?src=

[Eoganacht]

Thanks for sharing that very interesting article ScienceFirst. Despite their underestimation of the significance of TLD1433 there are several topics which are very much worth a read - particularly the section on immunogenic cell death and the concluding discussion of the obstacles pdt faces trying to enter the mainstream. "PDT is gaining increasing attention due to its immunomodulatory

[Eoganacht]

I hope these researchers take due note of the trial results you sent them. Sometimes these articles have long lead times which prevent the writers from including the latest research. This happened with an article of Dr. Peter Black a few years ago where TLD1433 barely got a mention. He included more extensive information about TLD1433 in later articles and is now the PI of our UBC clinical study